Versartis Raises $21M in Second Round
February 16, 2011

Versartis Inc. has completed a $21 million second round of funding.  The round was led by New Leaf Venture Partners, which has an office in Menlo Park.

London-based Advent Venture Partners, Geneva-based Index Ventures and Mountain View-based Amunix Inc. also joined in the round.

Mountain View-based Versartis is biotechnology startup developing therapeutics for patients with endocrine disorders.

The company plans to use the proceeds to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency in adult and pediatric patients.

Versartis also has expanded its board of directors to five members: Dr. Srini Akkaraju, managing director of New Leaf Venture Partners; Kevin Johnson, partner at Index Ventures; Shahzad Malik, general partner at Advent Venture Partners; Willem Stemmer, CEO of Amunix; and Jeffrey L. Cleland, CEO of Versartis.